- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
FDA Approves Medtronic’s Simplera Continuous Glucose Monitor
Partnership with Abbott for Simplera CGM will expand access to the advanced automated insulin delivery.
Image Credit: Adobe Stock Images/Wanlop
The FDA has approved Medtronic’s Simplera continuous glucose monitor (CGM), with the company stating that it offers a smaller, more discreet, and user-friendly device to help patients manage their diabetes. Medtronic stated that the approval marks a significant advancement in CGM offerings by eliminating the need for overtape and simplifying the insertion process. Medtronic also announced a global partnership with Abbott to expand CGM options for people living with diabetes.1
"Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and Smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world. We look forward to offering our Simplera™ platform alongside this integrated CGM to bring more choice to people living with diabetes within one seamless Medtronic experience," said Que Dallara, EVP, president, Medtronic Diabetes, in a press release.
Under terms of the deal, the companies will collaborate on an integrated CGM based on Abbott's most advanced CGM platform, with Abbott providing a CGM that will work exclusively with Medtronic smart dosing devices and software across both automated insulin delivery and Smart MDI systems. Moving forward, these systems will be sold only by Medtronic, including the Abbott-based CGM.1
"This partnership pairs two global leaders in glucose sensing technology and insulin delivery," said Jared Watkin, EVP, diabetes care business, Abbott, in the press release. "Abbott's CGM technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic's advanced insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living."
Reference
Medtronic announces FDA approval of Simplera™ CGM and global partnership with Abbott. PR Newswire. August 7, 2024. Accessed August 7, 2024. https://www.prnewswire.com/news-releases/medtronic-announces-fda-approval-of-simplera-cgm-and-global-partnership-with-abbott-302216165.html
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
September 16th 2024Results from the ADvocate 1, ADvocate 2, and ADhere clinical trials found that patients treated with Ebglyss 38% of patients with moderate-to-severe atopic dermatitis achieved clear or almost-clear skin after 16 weeks of treatment.
FDA Approves Subcutaneous Tecentriq Hybreza for All Adult Indications of IV Form of Tecentriq
September 13th 2024Subcutaneous Tecentriq Hybreza will provide patients and physicians increased flexibility for administration of the immunotherapy across approved indications for Tecentriq, including non–small cell lung cancer, small cell lung cancer, and hepatocellular carcinoma.
